Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

English version České info

Background:
Pancreatic cancer has an extremely poor prognosis and prolonged survival is achieved only by resection with macroscopic tumor clearance. There is a strong rationale for a neoadjuvant approach, since a relevant percentage of pancreatic cancer patients present with non-metastatic but locally advanced disease and microscopic incomplete resections are common. The objective of the present analysis was to systematically review studies concerning the effects of neoadjuvant therapy on tumor response, toxicity, resection, and survival percentages in pancreatic cancer.

Methods and Findings:
Trials were identified by searching MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from 1966 to December 2009 as well as through reference lists of articles and proceedings of major meetings. Retrospective and prospective studies analyzing neoadjuvant radiochemotherapy, radiotherapy, or chemotherapy of pancreatic cancer patients, followed by re-staging, and surgical exploration/resection were included. Two reviewers independently extracted data and assessed study quality. Pooled relative risks and 95% confidence intervals were calculated using random-effects models. Primary outcome measures were proportions of tumor response categories and percentages of exploration and resection. A total of 111 studies (n = 4,394) including 56 phase I–II trials were analyzed. A median of 31 (interquartile range [IQR] 19–46) patients per study were included. Studies were subdivided into surveys considering initially resectable tumors (group 1) and initially non-resectable (borderline resectable/unresectable) tumors (group 2). Neoadjuvant chemotherapy was given in 96.4% of the studies with the main agents gemcitabine, 5-FU (and oral analogues), mitomycin C, and platinum compounds. Neoadjuvant radiotherapy was applied in 93.7% of the studies with doses ranging from 24 to 63 Gy. Averaged complete/partial response probabilities were 3.6% (95% CI 2%–5.5%)/30.6% (95% CI 20.7%–41.4%) and 4.8% (95% CI 3.5%–6.4%)/30.2% (95% CI 24.5%–36.3%) for groups 1 and 2, respectively; whereas progressive disease fraction was estimated to 20.9% (95% CI 16.9%–25.3%) and 20.8% (95% CI 14.5%–27.8%). In group 1, resectability was estimated to 73.6% (95% CI 65.9%–80.6%) compared to 33.2% (95% CI 25.8%–41.1%) in group 2. Higher resection-associated morbidity and mortality rates were observed in group 2 versus group 1 (26.7%, 95% CI 20.7%–33.3% versus 39.1%, 95% CI 29.5%–49.1%; and 3.9%, 95% CI 2.2%–6% versus 7.1%, 95% CI 5.1%–9.5%). Combination chemotherapies resulted in higher estimated response and resection probabilities for patients with initially non-resectable tumors (“non-resectable tumor patients”) compared to monotherapy. Estimated median survival following resection was 23.3 (range 12–54) mo for group 1 and 20.5 (range 9–62) mo for group 2 patients.

Conclusions:
In patients with initially resectable tumors (“resectable tumor patients”), resection frequencies and survival after neoadjuvant therapy are similar to those of patients with primarily resected tumors and adjuvant therapy. Approximately one-third of initially staged non-resectable tumor patients would be expected to have resectable tumors following neoadjuvant therapy, with comparable survival as initially resectable tumor patients. Thus, patients with locally non-resectable tumors should be included in neoadjuvant protocols and subsequently re-evaluated for resection.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages. PLoS Med 7(4): e32767. doi:10.1371/journal.pmed.1000267
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000267

Souhrn

Zdroje

1. JemalA

SiegelR

WardE

HaoY

XuJ

2009 Cancer statistics, 2009. CA Cancer J Clin 59 225 249

2. HeinemannV

BoeckS

HinkeA

LabiancaR

LouvetC

2008 Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8 82

3. SultanaA

Tudur SmithC

CunninghamD

StarlingN

NeoptolemosJP

2008 Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 99 6 13

4. BilimoriaKY

BentremDJ

KoCY

StewartAK

WinchesterDP

2007 National failure to operate on early stage pancreatic cancer. Ann Surg 246 173 180

5. ShrikhandeSV

KleeffJ

ReiserC

WeitzJ

HinzU

2007 Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 14 118 127

6. KleeffJ

FriessH

BuchlerMW

2007 Neoadjuvant therapy for pancreatic cancer. Br J Surg 94 261 262

7. AdlerG

SeufferleinT

BischoffSC

BrambsHJ

FeuerbachS

2007 [S3-Guidelines “Exocrine pancreatic cancer” 2007]. Z Gastroenterol 45 487 523

8. TemperoM

ArnolettiJP

Ben-JosefE

BhargavaP

CasperES

2007 Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 5 998 1033

9. SiriwardanaHP

SiriwardenaAK

2006 Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg 93 662 673

10. KleeffJ

ReiserC

HinzU

BachmannJ

DebusJ

2007 Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 245 566 572

11. EspositoI

KleeffJ

BergmannF

ReiserC

HerpelE

2008 Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15 1651 1660

12. GaedckeJ

GunawanB

GradeM

SzokeR

LierschT

2009 The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg

13. VerbekeCS

LeitchD

MenonKV

McMahonMJ

GuillouPJ

2006 Redefining the R1 resection in pancreatic cancer. Br J Surg 93 1232 1237

14. MichalskiCW

KleeffJ

WenteMN

DienerMK

BuchlerMW

2007 Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 94 265 273

15. StockenDD

BuchlerMW

DervenisC

BassiC

JeekelH

2005 Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 92 1372 1381

16. WolffRA

VaradhacharyGR

EvansDB

2008 Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol 15 2773 2786

17. BakkevoldKE

ArnesjoB

DahlO

KambestadB

1993 Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater–results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A 698 703

18. GITSG 1987 Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59 2006 2010

19. KlinkenbijlJH

JeekelJ

SahmoudT

van PelR

CouvreurML

1999 Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 776 782; discussion 782-774

20. NeoptolemosJP

StockenDD

FriessH

BassiC

DunnJA

2004 A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 1200 1210

21. OettleH

PostS

NeuhausP

GellertK

LangrehrJ

2007 Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297 267 277

22. TakadaT

AmanoH

YasudaH

NimuraY

MatsushiroT

2002 Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 1685 1695

23. Van LaethemJL

MornexF

AzriaD

van TienhovenG

MauerM

2009 Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: updated results of a randomized EORTC/FFCD/GERCOR phase II study (40013-22012/9203). J Clin Oncol 27 4527

24. PilepichMV

MillerHH

1980 Preoperative irradiation in carcinoma of the pancreas. Cancer 46 1945 1949

25. WhittingtonR

SolinL

MohiuddinM

CantorRI

RosatoFE

1984 Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 54 1991 1998

26. MoherD

CookDJ

EastwoodS

OlkinI

RennieD

1999 Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 1896 1900

27. MoherD

LiberatiA

TetzlaffJ

AltmanDG

2009 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6 e1000097 doi:10.1371/journal.pmed.1000097

28. TemperoM

AlasadiR

ArnolettiJP

BehrmanS

Ben-JosefE

2009 National Comprehensive Cancer Network: Practice guidelines in oncology—v.1.2008: Pancreatic adenocarcinoma. Available at www.nccn.org

29. TherasseP

ArbuckSG

EisenhauerEA

WandersJ

KaplanRS

2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 205 216

30. FreemanMF

TukeyJW

1950 Transformation related to the angular and the square root. Ann Math Statist 21 607 611

31. MillerJJ

1978 The inverse of the Freeman-Tukey double arcsine transformation. Am Stat 32 138

32. RouderJN

SpeckmanPL

2004 An evaluation of the Vincentizing method of forming group-level response time distributions. Psychon Bull Rev 11 419 427

33. ThompsonSG

1993 Controversies in meta-analysis: the case of the trials of serum cholesterol reduction. Stat Methods Med Res 2 173 192

34. RegineWF

WinterKA

AbramsRA

SafranH

HoffmanJP

2008 Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299 1019 1026

35. SchaferM

MullhauptB

ClavienPA

2002 Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 236 137 148

36. BirkmeyerJD

SiewersAE

FinlaysonEV

StukelTA

LucasFL

2002 Hospital volume and surgical mortality in the United States. N Engl J Med 346 1128 1137

37. BuchlerMW

WagnerM

SchmiedBM

UhlW

FriessH

2003 Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 138 1310 1314; discussion 1315

38. BrunnerTB

GrabenbauerGG

MeyerT

GolcherH

SauerR

2007 Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer 7 41

39. WarshawAL

GuZY

WittenbergJ

WaltmanAC

1990 Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 125 230 233

40. NeoptolemosJ

BüchlerM

StockenDD

GhanehP

SmithD

2009 ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 27 4505

41. HartwigW

HackertT

HinzU

HassenpflugM

StrobelO

2009 Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg 250 81 87

42. Cancer-Research-UK 2009 CancerStats key facts on pancreatic (pancreas) cancer. Available at info.cancerresearchuk.org

43. TsaiJY

IannittiDA

SafranH

2003 Combined modality therapy for pancreatic cancer. Semin Oncol 30 71 79

44. LouvetC

LabiancaR

HammelP

LledoG

ZampinoMG

2005 Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23 3509 3516